In 40 ovarian cancers, it was reported that while high hCtr1 expression is associated with chemosensitivity of Pt-based drugs, patients with low hCtr1 and high hCtr2 in their tumors have poor treatment outcomes and shorter overall survival (OS) time [28]. Here, SLC31A2 is linked to ovarian carcinoma.